Qualigen therapeutics announces formation and first meeting of qn-302 scientific advisory board

Carlsbad, calif., aug. 18, 2022 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces it has formed a scientific advisory board (sab) in support of the development of its lead therapeutic candidate qn-302 for the potential treatment of pancreatic cancer and other g4-prevalent solid tumors.
QLGN Ratings Summary
QLGN Quant Ranking